Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02114931 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase 3 study of Arthritis, Rheumatoid, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 467
- Enrollment target
- 20
- Study locations
NCT02114931 is a Phase 3 study of Arthritis, Rheumatoid that has completed, run by Amgen. The registered enrollment target is 467 participants, below the 624-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT02114931, a Phase 3 study of Arthritis, Rheumatoid, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 467 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this open-label study is to evaluate the long-term safety and efficacy of ABP 501 in adults with moderate to severe rheumatoid arthritis (RA).
Conditions Studied
Interventions
- BIOLOGICAL ABP 501
Study Locations (20)
California
- Research Site - Covina
- Research Site - El Cajon
- Research Site - Hemet
- Research Site - Palm Desert
- Research Site - Van Nuys
- Research Site - Whittier
Florida
- Research Site - Miami
- Research Site - Orlando
- Research Site - Sarasota
Arizona
- Research Site - Peoria
- Research Site - Scottsdale
Maryland
- Research Site - Hagerstown
- Research Site - Wheaton
Alabama
- Research Site - Huntsville
Connecticut
- Research Site - Danbury
Georgia
- Research Site - Sandy Springs
Kentucky
- Research Site - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 467 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02114931
The ClinicalTrials.gov registry entry for NCT02114931 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 467 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 624-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (25% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 1 intervention - of which ABP 501 is the first listed.
NCT02114931 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02114931 about?
NCT02114931 is a clinical study titled "Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis". The purpose of this open-label study is to evaluate the long-term safety and efficacy of ABP 501 in adults with moderate to severe rheumatoid arthritis (RA).
What is the current status of trial NCT02114931?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 467 participants. The study started on 2014-04. Estimated completion is 2016-04.
What conditions does trial NCT02114931 study?
This clinical trial studies the following conditions: Arthritis, Rheumatoid.
What interventions are being tested in trial NCT02114931?
The interventions under investigation include: ABP 501 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02114931?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02114931 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Rheumatoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
COMPLETED · Phase 3
-
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
COMPLETED · Phase 3
-
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.